|
1
|
Tateo V, Manuzzi L, De Giglio A, Parisi C,
Lamberti G, Campana D and Pantaleo MA: Immunobiology of thymic
epithelial tumors: Implications for immunotherapy with immune
checkpoint inhibitors. Int J Mol Sci. 21:90562020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JH, Beasley MB, Chirieac LR, Dacic S, Duhig E, et
al: The 2015 World Health Organization Classification of Lung
Tumors: Impact of genetic, clinical and radiologic advances since
the 2004 classification. J Thorac Oncol. 10:1243–1260. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Detterbeck FC, Nicholson AG, Kondo K, Van
Schil P and Moran C: The Masaoka-Koga stage classification for
thymic malignancies: clarification and definition of terms. J
Thorac Oncol: Cancer. 6:S1710–1716. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lababede O and Meziane MA: The eighth
edition of TNM staging of lung cancer: Reference chart and
diagrams. Oncologist. 23:844–848. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kondo K: Therapy for thymic epithelial
tumors. Gen Thorac Cardiovasc Surg. 62:468–474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shimosato Y, Mukai K and Matsuno Y: Tumors
of the mediastinum. AFIP Atlas of Tumor Pathology, Series 4. Armed
Forces Institute of Pathology; Washington, DC: 2010
|
|
7
|
Kondo K and Monden Y: Therapy for thymic
epithelial tumors: A clinical study of 1,320 patients from Japan.
Ann Thorac Surg. 76:878–885. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Berghmans T, Durieux V, Holbrechts S,
Jungels C, Lafitte JJ, Meert AP, Moretti L, Ocak S, Roelandts M, et
al: Systemic treatments for thymoma and thymic carcinoma: A
systematic review. Lung Cancer. 126:25–31. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Girard N, Ruffini E, Marx A, Faivre-Finn C
and Peters S: Thymic epithelial tumours: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
26:v40–v55. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scorsetti M, Leo F, Trama A, D'Angelillo
R, Serpico D, Macerelli M, Zucali P, Gatta G and Garassino MC:
Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 99:332–350.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kelly RJ, Petrini I, Rajan A, Wang Y and
Giaccone G: Thymic malignancies: from clinical management to
targeted therapies. J Clin Oncol. 29:4820–4827. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suzuki E, Sasaki H, Kawano O, Endo K,
Haneda H, Yukiue H, Kobayashi Y, Yano M and Fujii Y: Expression and
mutation statuses of epidermal growth factor receptor in thymic
epithelial tumors. Jpn J Clin Oncol. 36:351–356. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cimpean AM, Raica M, Encica S, Cornea R
and Bocan V: Immunohistochemical expression of vascular endothelial
growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and
pathologic conditions of the human thymus. Ann Anat. 190:238–245.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Girard N, Teruya-Feldstein J, Payabyab EC,
Riely GJ, Rusch VW, Kris MG and Zakowski MF: Insulin-like growth
factor-1 receptor expression in thymic malignancies. J Thorac
Oncol. 5:1439–1446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weissferdt A, Fujimoto J, Kalhor N,
Rodriguez J, Bassett R, Wistuba II and Moran CA: Expression of PD-1
and PD-L1 in thymic epithelial neoplasms. Mod Pathol. 30:826–833.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zucali PA, De Pas T, Palmieri G, Favaretto
A, Chella A, Tiseo M, Caruso M, Simonelli M, Perrino M, et al:
Phase II study of everolimus in patients with thymoma and thymic
carcinoma previously treated with cisplatin-based chemotherapy. J
Clin Oncol. 36:342–349. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thomas A, Rajan A, Berman A, Tomita Y,
Brzezniak C, Lee MJ, Lee S, Ling A, Spittler AJ, et al: Sunitinib
in patients with chemotherapy-refractory thymoma and thymic
carcinoma: an open-label phase 2 trial. Lancet Oncol. 16:177–186.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kishibuchi R, Kondo K, Soejima S, Tsuboi
M, Kajiura K, Kawakami Y, Kawakita N, Sawada T, Toba H, et al: DNA
methylation of GHSR, GNG4, HOXD9 and SALL3 is a common epigenetic
alteration in thymic carcinoma. Int J Oncol. 56:315–326.
2020.PubMed/NCBI
|
|
19
|
Moskalev EA, Jandaghi P, Fallah M,
Manoochehri M, Botla SK, Kolychev OV, Nikitin EA, Bubnov VV, von
Knebel Doeberitz M, et al: GHSR DNA hypermethylation is a common
epigenetic alteration of high diagnostic value in a broad spectrum
of cancers. Oncotarget. 6:4418–4427. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kojima M and Kangawa K: Ghrelin: Structure
and Function. Physiol Rev. 85:495–522. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Howard AD, Feighner SD, Cully DF, Arena
JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC,
et al: A receptor in pituitary and hypothalamus that functions in
growth hormone release. Science. 273:974–977. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Seim I, Herington AC and Chopin LK: New
insights into the molecular complexity of the ghrelin gene locus.
Cytokine Growth Factor Rev. 20:297–304. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: introduction to the 2015 World Health
Organization classification of tumors of the lung, pleura, thymus,
and heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luque RM, Sampedro-Nuñez M, Gahete MD,
Ramos-Levi A, Ibáñez-Costa A, Rivero-Cortés E, Serrano-Somavilla A,
Adrados M, Culler MD, et al: In1-ghrelin, a splice variant of
ghrelin gene, is associated with the evolution and aggressiveness
of human neuroendocrine tumors: Evidence from clinical, cellular
and molecular parameters. Oncotarget. 6:19619–19633. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin T-C and Hsiao M: Ghrelin and cancer
progression. Biochim Biophys Acta Rev Cancer. 1868:51–57. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Volante M, Allia E, Fulcheri E, Cassoni P,
Ghigo E, Muccioli G and Papotti M: Ghrelin in fetal thyroid and
follicular tumors and cell lines: expression and effects on tumor
growth. Am J Pathol. 162:645–654. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cassoni P, Papotti M, Ghè C, Catapano F,
Sapino A, Graziani A, Deghenghi R, Reissmann T, Ghigo E, et al:
Identification, characterization, and biological activity of
specific receptors for natural (ghrelin) and synthetic growth
hormone secretagogues and analogs in human breast carcinomas and
cell lines. J Clin Endocrinol Metab. 86:1738–1745. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bai RX, Wang WP, Zhao PW and Li CB:
Ghrelin attenuates the growth of HO-8910 ovarian cancer cells
through the ERK pathway. Braz J Med Biol Res. 49:e50432016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Díaz-Lezama N, Hernández-Elvira M,
Sandoval A, Monroy A, Felix R and Monjaraz E: Ghrelin inhibits
proliferation and increases T-type Ca2+ channel
expression in PC-3 human prostate carcinoma cells. Biochem Biophys
Res Commun. 403:24–29. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cassoni P, Allia E, Marrocco T, Ghè C,
Ghigo E, Muccioli G and Papotti M: Ghrelin and cortistatin in lung
cancer: Expression of peptides and related receptors in human
primary tumors and in vitro effect on the H345 small cell carcinoma
cell line. J Endocrinol Invest. 29:781–790. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin TC, Liu YP, Chan YC, Su CY, Lin YF,
Hsu SL, Yang CS and Hsiao M: Ghrelin promotes renal cell carcinoma
metastasis via Snail activation and is associated with poor
prognosis. J Pathol. 237:50–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dixit VD, Weeraratna AT, Yang H, Bertak D,
Cooper-Jenkins A, Riggins GJ, Eberhart CG and Taub DD: Ghrelin and
the growth hormone secretagogue receptor constitute a novel
autocrine pathway in astrocytoma motility. J Biol Chem.
281:16681–16690. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Waseem T, Javaid ur R, Ahmad F, Azam M and
Qureshi MA: Role of ghrelin axis in colorectal cancer: A novel
association. Peptides. 29:1369–1376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Duxbury MS, Waseem T, Ito H, Robinson MK,
Zinner MJ, Ashley SW and Whang EE: Ghrelin promotes pancreatic
adenocarcinoma cellular proliferation and invasiveness. Biochem
Biophys Res Commun. 309:464–468. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ibáñez-Costa A, Gahete MD, Rivero-Cortés
E, Rincón-Fernández D, Nelson R, Beltrán M, de la Riva A, Japón MA,
Venegas-Moreno E, et al: In1-ghrelin splicing variant is
overexpressed in pituitary adenomas and increases their aggressive
features. Sci Rep. 5:87142015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hormaechea-Agulla D, Gahete MD,
Jiménez-Vacas JM, Gómez-Gómez E, Ibáñez-Costa A, L-López F,
Rivero-Cortés E, Sarmento-Cabral A, Valero-Rosa J, et al: The
oncogenic role of the In1-ghrelin splicing variant in prostate
cancer aggressiveness. Mol Cancer. 16:1462017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gahete MD, Córdoba-Chacón J,
Hergueta-Redondo M, Martínez-Fuentes AJ, Kineman RD, Moreno-Bueno
G, Luque RM and Castaño JP: A Novel Human Ghrelin Variant
(In1-Ghrelin) and Ghrelin-O-Acyltransferase Are Overexpressed in
Breast Cancer: Potential Pathophysiological Relevance. PLoS One.
6:e233022011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rincón-Fernández D, Culler MD, Tsomaia N,
Moreno-Bueno G, Luque RM, Gahete MD and Castaño JP: In1-ghrelin
splicing variant is associated with reduced disease-free survival
of breast cancer patients and increases malignancy of breast cancer
cells lines. Carcinogenesis. 39:447–457. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jeffery PL, Murray RE, Yeh AH, McNamara
JF, Duncan RP, Francis GD, Herington AC and Chopin LK: Expression
and function of the ghrelin axis, including a novel preproghrelin
isoform, in human breast cancer tissues and cell lines. Endocr
Relat Cancer. 12:839–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Barzon L, Pacenti M, Masi G, Stefani AL,
Fincati K and Palù G: Loss of growth hormone secretagogue receptor
1a and overexpression of type 1b receptor transcripts in human
adrenocortical tumors. Oncology. 68:414–421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Herrera-Martínez AD, Gahete MD,
Sánchez-Sánchez R, Salas RO, Serrano-Blanch R, Salvatierra Á,
Hofland LJ, Luque RM, Gálvez-Moreno MA, et al: The components of
somatostatin and ghrelin systems are altered in neuroendocrine lung
carcinoids and associated to clinical-histological features. Lung
Cancer. The components of somatostatin and ghrelin systems are
altered in neuroendocrine lung carcinoids and associated to
clinical-histological features. Lung Cancer. 109:128–136. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
De Vriese C, Grégoire Fo, De Neef P,
Robberecht P and Delporte C: Ghrelin is produced by the human
erythroleukemic HEL cell line and involved in an autocrine pathway
leading to cell proliferation. Endocrinology. 146:1514–1522. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Leung PK, Chow KB, Lau PN, Chu KM, Chan
CB, Cheng CH and Wise H: The truncated ghrelin receptor polypeptide
(GHS-R1b) acts as a dominant-negative mutant of the ghrelin
receptor. Cell Signal. 19:1011–1022. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Takahashi K, Furukawa C, Takano A,
Ishikawa N, Kato T, Hayama S, Suzuki C, Yasui W, Inai K, et al: The
neuromedin U-growth hormone secretagogue receptor 1b/neurotensin
receptor 1 oncogenic signaling pathway as a therapeutic target for
lung cancer. Cancer Res. 66:9408–9419. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gómez-Gómez E, Jiménez-Vacas JM,
Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM,
León-González AJ, Valero-Rosa J, Fernández-Rueda JL,
González-Serrano T, et al: Plasma ghrelin O-acyltransferase (GOAT)
enzyme levels: A novel non-invasive diagnosis tool for patients
with significant prostate cancer. J Cell Mol Med. 22:5688–5697.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Herrera-Martínez AD, Gahete MD,
Sánchez-Sánchez R, Alors-Perez E, Pedraza-Arevalo S, Serrano-Blanch
R, Martínez-Fuentes AJ, Gálvez-Moreno MA, Castaño JP, et al:
Ghrelin-O-Acyltransferase (GOAT) enzyme as a novel potential
biomarker in gastroenteropancreatic neuroendocrine tumors. Clin
Transl Gastroenterol. 9:1962018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
49
|
Brena RM, Plass C and Costello JF: Mining
methylation for early detection of common cancers. PLoS Med.
3:e4792006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ordway JM, Budiman MA, Korshunova Y,
Maloney RK, Bedell JA, Citek RW, Bacher B, Peterson S, Rohlfing T,
et al: Identification of Novel High-Frequency DNA Methylation
Changes in Breast Cancer. PLoS One. 2:e13142007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Daugaard I, Dominguez D, Kjeldsen TE,
Kristensen LS, Hager H, Wojdacz TK and Hansen LL: Identification
and validation of candidate epigenetic biomarkers in lung
adenocarcinoma. Sci Rep. 6:358072016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Nakagawa T, Matsusaka K, Misawa K, Ota S,
Takane K, Fukuyo M, Rahmutulla B, Shinohara KI, Kunii N, et al:
Frequent promoter hypermethylation associated with human
papillomavirus infection in pharyngeal cancer. Cancer Lett.
407:21–31. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Verlaat W, Snijders PJF, Novianti PW,
Wilting SM, De Strooper LM, Trooskens G, Vandersmissen J, Van
Criekinge W, Wisman GB, et al: Genome-wide DNA methylation
profiling reveals methylation markers associated with 3q gain for
detection of cervical precancer and cancer. Clin Cancer Res:.
23:3813–3822. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Coppede F, Stoccoro A, Lazzarotti A,
Spisni R and Migliore L: Investigation of GHSR and GHRL methylation
in colorectal cancer. Epigenomics. 10:1525–1539. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Coppedè F, Stoccoro A, Nicolì V, Gallo R,
De Rosa A, Guida M, Maestri M, Lucchi M, Ricciardi R, et al:
Investigation of GHSR methylation levels in thymomas from patients
with Myasthenia Gravis. Gene. 752:1447742020. View Article : Google Scholar : PubMed/NCBI
|
